Every handoff in drug development is a place where timelines go to die.
In protein therapeutics and pDNA, the friction usually isn’t the science — it’s the seams. Vendor #1 to vendor #2. Research-grade to GMP. Cell line to fill/finish. Each handoff adds weeks, risk, and rework. Ask any CMC lead where programs slip and you’ll hear the same answer: the transitions.
One team. From cell line to 2,000L GMP.
- High-performance CHO cell lines. Custom plasmids in 2 weeks.
- One direct path to 2,000L, with no re-platforming.
- Bispecifics, ADCs, T-cell engagers, mRNA, viral vectors.
- Research to clinical to commercial, all under one roof.
Different molecules. Same principle: no friction.
Not a marketing line. An org chart.
The scientists who develop your cell line or plasmid are in the same building, on the same platform, as the people who take it to 2,000L. One accountable team owns your molecule from gene to GMP — not a relay of vendors pointing at each other when a timeline slips.
“From gene to GMP” — what does that actually mean?
It’s the full path most programs stitch together across 3–5 vendors: gene of interest → cell line or plasmid → process development → analytics → GMP manufacturing → release. Every arrow is a handoff where time and quality can leak. We put the whole path under one roof so the arrows disappear. Same science, fewer seams.
